



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 05-6-2008

Mr. Yasin Tahir,
Director General, IPO-Pakistan
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 10-5-2008 TO BE PUBLISHED 07-6-2008 IN THE
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 05-6-2008

To,

Mr. Manzoor Ahmed
Section Officer
Cabinet Secretariat
Cabinet Division
Government of Pakistan
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE WEEKENDING 10-5-2008 TO BE PUBLISHED 07-6-2008 IN THE GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23rd April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

478/2008	<u>05-5-2008</u> 1. Dr. Shahid Iqbal 2. Prof. Dr. Muhammad Iqbal Bhanger, Director, 3. Dr. Mubeena Akhtar, Sargodha, Pakistan	“An indigenous herbal system for oil stability”
479/2008	Schering Corporation, USA (Priority 07-5-07 USA)	“Gamma secretase modulators”
480/2008	Novartis AG, Switzerland (Priority 07-5-07 Europe)	“Organic compounds”
481/2008	<u>06-5-2008</u> AstraZeneca AB, Sweden (Priority 08-5-07 Sweden)	“Therapeutic compound 570”
482/2008	AstraZeneca AB, Japan (Priority 07-5-07 US)	“Novel compounds 694”
483/2008	Mr. Noor Muhammad Shaikh PCSIR, Karachi Provisional	“2-stroke engine to 4-stroke engine conversion technology”
484/2008	Mr. Munawar Ahmed Malik, Rawalpindi, Pakistan. Provisional	“Solar thermal tile”
485/2008	Mr. Munawar Ahmed Malik, Rawalpindi, Pakistan. Provisional	“Low temperature mechanical engine”
486/2008	Mr. Munawar Ahmed Malik, Rawalpindi, Pakistan. Provisional	“Solar thermal water pump”
487/2008	Mr. Munawar Ahmed Malik, Rawalpindi, Pakistan. Provisional	“Solar mineral water unit”

488/2008	Mr. Munawar Ahmed Malik, Rawalpindi, Pakistan. Provisional	“Eyesight meter”
489/2008	Mr. Munawar Ahmed Malik, Rawalpindi, Pakistan. Provisional	“Solar Roof tile”
490/2008	Amira Pharmaceuticals, Inc. USA (Priority 08-5-07 USA)	“5-lipoxygenase-activating protein (FLAP) inhibitors”
491/2008	1. Singh, Ajoy I. 2. Rathore, Jaswant, India (Priority 07-5-07 India)	“A system for laser photoablation within a lens”
492/2008	Otsuka Pharmaceutical Co., Ltd. Japan (Priority 08-5-07 Japan)	“Epoxy compound and method for manufacturing the same”
493/2008	Siemens VAI Metals, Technologies GmbH & Co., Austria (Priority 09-5-07 Austria)	“Method for producing moldings”
494/2008	F. Hoffmann-La Roche AG, Switzerland Divisional	“Pharmaceutically acceptable salt of the compound 2-(2-amino-1,6-dihydro-6- oxo-purin-9-yl)methoxy-3-hydro-1- propanyl-l-valinate”
495/2008	<u>07-5-2008</u> Pfizer Inc. USA (Priority 09-5-07 USA)	“Substituted heterocyclic derivatives and their pharmaceutical use and compositions”
496/2008	N. V. Organon. Netherlands (Priority 07-5-07 Europe)	“New progesterone receptor modulators”
497/2008	DyStar Textilfarben GmbH & Co. Deutschland KG, Germany (Priority 09-5-07 Germany)	“Vat Dyes”
498/2008	Novartis AG, Switzerland (Priority 09-5-07 Europe)	“Substituted imidazopyriazines as lipid kinase inhibitors”

499/2008	<u>08-5-2008</u> Merck Patent GmbH, Germany (Priority 10-5-07 DE)	“S. specification”
500/2008	Ortloff Engineers, Ltd. USA (Priority 17-5-07 US)	“Liquefied natural gas processing”
501/2008	Pfizer Limited, United Kingdom (Priority 10-5-07 USA)	“Azetidines”
502/2008	Pfizer Inc., USA (Priority 11-5-07 USA)	“Amino-heterocyclic compounds”
503/2008	1 Mr. Muhammad Rauf, 2. Askari Begum, 3. Mr. Abdul Ali, 4. Mr. Muhammad Ali Imran PCSIR, Karachi Pakistan	“A process for the production dehydrated fried value added potato chips”
504/2008	SmithKline Beecham Corporation, USA (Priority 10-5-07 USA)	“Quinoxaline derivatives as p13 kinase inhibitors”
505/2008	Maschinenfabrik Rieter AG, Switzerland (Priority 10-5-07 Germany)	“Transport belt for transporting a fibre strand “
506/2008	<u>09-5-2008</u> Nycomed GmbH, Germany (Priority 16-5-07 Europe)	“Novel pyrazolone-derivates”
507/2008	1.Riken, 2. Otsuka Pharmaceutical Co., Ltd. 3. Hayashi Kasei Co., Ltd. Japan (Priority 09-5-07 Japan)	“Single-chain circular rna and method of producing the same”
508/2008	Zuei-Ling Lin, Taiwan R. O. C.,	“Method of reducing frictional resistance between ship body and water by releasing gases in water”

509/2008	Novartis AG, Switzerland (Priority 11-5-07 USA)	“Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors”
	<u>10-5-2008</u>	
510/2008	Rashingkar Laxmikant Vishnupant, India (Priority 10-5-07 India)	“A liquid saving flow control device”
511/2008	1. Bayer Schering Pharma Aktiengesellschaft and 2. Bayer Healthcare AG, Germany (Priority 11-5-07 USA)	“Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity”
512/2008	Bayer HealthCare Ag, Germany (Priority 24-12-99 Germany) Divisional	“Process for the preparation of substituted oxazoliinone”
513/2008	Nokia Corporation Finland (Priority 23-8-05 USA) Divisional	“Redio link control unacknowledged mode header optimization”
514/2008	Plasco Energy Group Inc., Canada (Priority 11-5-07 USA)	“A gas reformulation system comprising means to optimise the effectiveness of gas conversion”

BBBBBBBBBB

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.


Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

469/2002	Boehringer Ingelheim Pharma GmbH & Co. KG. Germany.	“Capsules for inhalation” (INT: CL, A61K 31/38)	139539
----------	--	--	--------

The invention relates to capsules for inhalation (inhalettes) made from specific capsule materials with a reduced moisture content, which contain the active substance tiotropium in the form of powdered preparations and are characterized by increased stability.

23/2003	Warner-Lambert Company LLC. USA.	“2-(pyridine-2-ylamino)-pyrido [2, 3 -d] pyrimidin-7-one” (C07D 213/06)	139540
---------	--	---	--------

The present invention provides substituted 2-aminopyridine useful in treating cell proliferative disorders. The novel compound of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4).




343/2004 Janssen Pharmaceutica
N.V.
Belgium.

“Quinazoline compound”

(C07D 498/08)

139541

The present invention concerns the compound
of formula



the TV-oxide form, and the
stereochemically isomeric form thereof,
wherein

Z represents NH; Y represents $-C_{3-9}$ alkyl-, $-C_{2-9}$ alkenyl-, $-C_{3-7}$ alkyl-CO-NH optionally substituted with amino, mono- or di(C_{1-4} alkyl)amino or C_{1-4} alkyloxycarbonylamino-, $-C_{3-7}$ alkenyl-CO-NH- optionally substituted with amino, mono- or di(C_{1-4} alkyl)amino- or C_{1-4} alkyloxycarbonylamino-, $-C_{1-5}$ alkyl-CO NR^{13} - C_{1-5} alkyl-, $-C_{1-5}$ alkyl- NR^{14} -CO- C_{1-5} alkyl-, C_{1-6} alkyl-CO-NH-, $-C_{1-5}$ alkyl-CONR¹⁵- C_{1-5} alkyl-, $-C_{1-3}$ alkyl-NH-CO-Het²⁰-, $-C_{1-2}$ alkyl-CO-Het²¹-CO-, $-C_{1-2}$ alkyl-NH-CO-CR¹⁶R¹⁷-NH-, $-C_{1-2}$ alkyl-CO-NH-CR¹⁸R¹⁹-CO-, $-C_{1-2}$ alkyl-CO-NR²⁰- C_{1-3} alkyl-CO-, or-NR²²-CO- C_{1-3} alkyl-NH-; X1 represents a direct bond, O or $-O-C_{1-2}$ alkyl-; X represents a direct bond, $-CO-C_{1-2}$ alkyl-, NR^{12} , $-NR^{12}-C_{1-2}$ alkyl-, $-O-N=CH-$ or $-C_{1-2}$ alkyls-, R^1 and R^2 each independently represents hydrogen or halo;

R^3 represents hydrogen; R^4 represents hydrogen or C_{1-4} alkyloxy; R^{12} and R^{13} each independently represents hydrogen or C_{1-4} alkyl; R^{14} and R^{15} represents hydrogen; R^{16} and R^{17} each independently represent hydrogen or R^{18} and R^{19} each independently represent hydrogen or C_{1-4} alkyl optionally substituted with phenyl or hydroxy; R^{20} and R^{21} each independently represent hydrogen or C_{1-4} alkyl optionally substituted with C_{1-4} alkyloxy; Het²⁰, Het²¹, and Het²² each independently represent a heterocycle selected

from the group consisting pyrrolidinyl, 2-pyrrolidinonyl or piperidinyl optionally substituted with hydroxyl.

616/2004 Pfizer Products Inc.
USA.

“Modified human insulin-like growth factor I receptor (IGF-IR) antibodies”

(C07K 16/18 , A61K 39/395)

139542

The present invention relates to human monoclonal antibody or antigen-binding portion thereof wherein the antibody specifically binds to human insulin-like growth factor I receptor (IGF-IR), and wherein the region of the light chain of said antibody comprises amino acid numbers 23 to 130 of amino acid sequence SEQ ID NO.5 that are for treatment of cancer.

336/2005 The Procter & Gamble
Company.
USA.

“Oral dosage form of a bisphosphonate”

(A61K 9/24)

139543

Oral dosage form of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastrointestinal tract provide delivery of the pharmaceutical composition to the lower gastrointestinal tract of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment

regimens and can lead to increased patient compliance with bisphosphonate Therapies.


995/2006 Janssen Pharmaceutica N.V. Belgium.

“A pharmaceutically acceptable salt of quinazoline derivative”

(C07D 498/08)

139544

The present invention concerns the compound of formula



the N--oxide form, the pharmaceutically acceptable addition salt and the stereochemically isomeric form thereof, wherein

Z represents NH; Y represents $-C_{3-9}$ alkyl-, $-C_{2-9}$ alkenyl-, $-C_{3-7}$ alkyl-CO-NH optionally substituted with amino, mono - or di(C_{1-4} alkyl)amino or C_{1-4} alkyloxycarbonylamino-, $-C_{3-7}$ alkenyl-CO-NH- optionally substituted with amino, mono- or di (C_{1-4} alkyl)amino- or C_{1-4} alkyloxycarbonylamino-, $-C_{1-5}$ alkyl-CO NR¹³- C_{1-5} alkyl-, $-C_{1-5}$ alkyl-NR¹⁴-CO- C_{1-5} alkyl-, C_{1-6} alkyl-CO-NH-, $-C_{1-5}$ alkyl-CONR¹⁵- C_{1-5} alkyl-, $-C_{1-3}$ alkyl-NH-CO-Het²⁰-, $-C_{1-2}$ alkyl-CO-Het²¹-CO-, $-C_{1-2}$ alkyl-NH-CO-CR¹⁶R¹⁷-NH-, $-C_{1-2}$ alkyl-CO-NH-CR¹⁸R¹⁹-CO-, $-C_{1-2}$ alkyl-CO-NR²⁰- C_{1-3} alkyl-CO-, or-NR²²-CO- C_{1-3} alkyl-NH-; X1 represents a direct bond, O or $-O-C_{1-2}$ alkyl-; X represents a direct bond, $-CO-C_{1-2}$ alkyl-, NR¹², $-NR^{12}-C_{1-2}$ alkyl-, $-O-N=CH-$ or $-C_{1-2}$ alkyls-, R¹ and R² each independently represents hydrogen or halo; R³ represents hydrogen; R⁴ represents hydrogen or C_{1-4} alkyloxy; R¹² and R¹³ each independently represents hydrogen or C_{1-4} alkyl; R¹⁴ and R¹⁵ represents hydrogen; R¹⁶ and R¹⁷ each independently represent hydrogen or R¹⁸ and R¹⁹ each independently

represent hydrogen or C₁₋₄alkyl optionally substituted with phenyl or hydroxy; R²⁰ and R²¹ each independently represent hydrogen or C₁₋₄alkyl optionally substituted with C₁₋₄alkyloxy; Het²⁰, Het²¹, and Het²² each independently represent a heterocycle selected from the group consisting pyrrolidinyl, 2-pyrrolidinonyl or piperidinyl optionally substituted with hydroxy.

~~~~~

**SEALING FEES DUE**

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

|        |                                                    |          |
|--------|----------------------------------------------------|----------|
| 139306 | Warnet-Lmert Company,<br>USA                       | 451/1996 |
| 139307 | Merck & Co. Inc,<br>USA                            | 603/2002 |
| 139308 | AstraZeneca AB<br>Sweden                           | 700/2004 |
| 139309 | Khurram Irshad P. E. C. H. S.<br>Karachi- Pakistan | 445/2005 |
| 139310 | Merck & Co., Inc.<br>USA                           | 754/2006 |

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Tel: 9215488